Miracor’s PiCSO® Impulse System highlighted as novel Therapy for Cardioprotected PCI at TCT 2015 in San Francisco

“PiCSO® offers promise to improve heart attack outcomes in the future”

Miracor Medical Systems GmbH (Miracor) announced today that during this year’s TCT conference in San Francisco, PiCSO has been highlighted in several sessions as offering new hope for Cardioprotection during Percutaneous Coronary Intervention (PCI). TCT (Transcatheter Cardiovascular Therapeutics) is the world's largest educational meeting specializing in interventional cardiovascular medicine and was held by the Cardiovascular Research Foundation (CRF) on October 10th - 16th, 2015 in San Francisco, CA, USA.

Myocardial salvage and the need for cardioprotection for patients with acute myocardial infarction (AMI) was a focus topic, yet again, at this year’s TCT conference.

“Despite recent improvements in the treatment of AMI, including shortened door-to-balloon times and advanced pharmacological strategies, survival has plateaued, and novel strategies are needed to reduce infarct size and improve clinical outcomes, especially in patients with large ST-segment elevation MI (STEMI),” stated Dr. Gregg W. Stone, Professor of Medicine at Columbia University College and Director of Cardiovascular Research and Education at the New York-Presbyterian Hospital Center for Interventional Vascular Therapies, during a symposium on novel strategies in PCI with focus on PiCSO Therapy. “In recent years, many approaches to improve reperfusion success and myocardial salvage have failed. Emerging data suggests that the effective delivery of PICSO improves myocardial perfusion and may reduce infarct size in STEMI patients,” he continued.

PiCSO is applied during the stenting procedure, directly following flow restoration and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury, damage to the myocardium caused by the stenting procedure itself.

“Further therapies to protect my patients - especially during complex PCI procedures are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” says Dr. Antonio Colombo, Director of Cardiovascular Interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”

“The feedback and enthusiasm we received during TCT on our latest achievements with the PiCSO Impulse System are very encouraging and show that PiCSO is addressing a huge, unmet clinical need in an area where most other new therapies have failed to demonstrate clinical benefit or effectiveness,“ says Dr. Werner Braun, former Managing Director at BIOTRONIK and now CEO of Miracor. “In the coming months, we will continue our commercial and clinical strategy in Europe and Asia, as well as our efforts to make this therapy available in the US,” he continues.
Learn more about PiCSO at www.miracormedical.com

About Miracor Medical Systems GmbH
Miracor Medical Systems GmbH (www.miracormedical.com) is an Austrian medical device company developing disruptive solutions to treat severe heart diseases; striving to bring back cardiac patients to normal life. Miracor develops and commercializes the PiCSO®  (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function.
The Miracor PiCSOAMI Impulse System is designed to treat acute ST-Segment Elevation Myocardial Infarction (‘STEMI’) patients and Non-ST-Segment Elevation Myocardial Infarction (‘NSTEMI’) patients by improving myocardial perfusion to complement percutaneous coronary intervention (PCI). PiCSOAMI is applied during PCI and designed to intermittently block the coronary sinus, a large vessel that collects blood from the heart muscle (myocardium), thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.